Stay updated on Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial
Sign up to get notified when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.
Latest updates to the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe study has officially closed to accrual and follow-up was completed on October 18, 2023, with new details on genotypic and phenotypic measures of resistance to integrase, protease, and reverse transcriptase genes, while previous ongoing study references and interim data summaries have been removed.SummaryDifference10%
- Check19 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference1%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe website has added new features while removing detailed options for participant groups, interventions, and various data fields for downloads.SummaryDifference2%
- Check41 days agoChange DetectedSeveral key resources related to HIV and clinical trials have been removed, including links to MedlinePlus and multiple PubMed articles.SummaryDifference0.3%
- Check48 days agoChange DetectedThe website has been updated to version v2.12.2, adding numerous links to clinical trial documents and PubMed articles, while removing the previous version v2.12.1.SummaryDifference3%
- Check55 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.0%
Stay in the know with updates to Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.